Interventional technology developer AngioDynamics has enrolled the first patient in its APEX-AV study to assess the performance of its AlphaVac F1885 system for treating pulmonary embolism (PE).
The study is a collaboration between AngioDynamics, the Pulmonary Embolism Response Team (PERT) Consortium, and artificial intelligence (AI) software company Viz.ai, it said. Principle investigators include Dr. William Keeling of Emory University in Atlanta, GA, and Dr. Mona Ranade of the University of California, Los Angeles, AngioDynamics said.
